Achieve Life Sciences ACHV 深 滬
等待開盤 07-23 09:30:00 美东时间
2.65
-0.010
-0.38%
華盛通- 最 高2.73
- 今 開2.67
- 成交量 73.56万股
- 最 低 2.605
- 昨 收 2.66
- 總市值 9191.55万
- 52周最高 5.31
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.84
- 委 比 -95.62%
- 總股本 3468.51万
- 歷史最高 970.00
- 量 比 0.54
- 振 幅 4.70%
- 歷史最低 1.84
- 每 手 1
- 風險率 0.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities
Achieve Life Sciences, Inc. completed an underwritten public offering of 15 million shares of common stock and warrants, raising $45 million. Proceeds will fund the advancement of cytisinicline, a potential treatment for nicotine dependence, toward FDA approval. The company is focused on addressing smoking and vaping cessation, with cytisinicline already granted Breakthrough Therapy designation. The offering was led by Citizens Capital Markets an...
06-30 23:52
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers NanoVibronix (NASDAQ:NAOV) shares increased by 45.2% to $1.25 during T...
06-27 05:05
Achieve Life Sciences shares are trading lower after the company announced a proposed underwritten public offering.
Achieve Life Sciences shares are trading lower after the company announced a pr...
06-27 04:05
Achieve Life Sciences Announces Proposed Underwritten Public Offering
Achieve Life Sciences Inc. announced a proposed underwritten public offering of its common stock and warrants. The company plans to use proceeds to advance cytisinicline, a potential smoking cessation treatment, through FDA approval and for general corporate purposes. The offering is subject to market conditions and SEC registration. Cytisinicline has shown promise in Phase 3 studies and seeks to address nicotine dependence, including vaping cess...
06-26 20:03
Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades
Achieve Life Sciences partners with Omnicom to develop a technology-driven launch strategy for cytisinicline, a potential treatment for nicotine dependence, targeting the U.S. market. The collaboration integrates AI and advanced technologies to enhance marketing precision and efficiency. Achieve recently submitted an NDA for cytisinicline, which has demonstrated success in Phase 3 studies for smoking cessation. Omnicom's expertise will support Ac...
06-26 20:02
Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation
Achieve Life Sciences submitted a New Drug Application (NDA) to the FDA for cytisinicline, a potential new treatment for nicotine dependence, targeting smoking cessation in adults. Backed by Phase 3 trials showing higher abstinence rates and favorable safety data, cytisinicline could be the first FDA-approved pharmacotherapy for nicotine dependence in two decades. The company aims to address the significant public health burden of smoking, affect...
06-26 20:01
Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference
Achieve Life Sciences, a specialty pharmaceutical company, announced it will present at the Jefferies Global Healthcare Conference June 3–5, 2025, in New York City. CEO Rick Stewart will speak on June 4 at 5:30 PM EDT. The company focuses on developing cytisinicline for smoking cessation, completing two Phase 3 studies and one Phase 2 study for vaping cessation. Achieve plans to submit a new drug application in June 2025 and has received Breakthr...
05-28 12:30
Achieve Life Sciences Q1 EPS $(0.37), Inline
Achieve Life Sciences (NASDAQ:ACHV) reported quarterly losses of $(0.37) per share which met the analyst consensus estimate. This is a 42.31 percent decrease over losses of $(0.26) per share from the same period last
05-13 19:30
Earnings Scheduled For May 13, 2025
Companies Reporting Before The Bell • Endeavour Silver (NYSE:EXK) is estimated ...
05-13 16:32
What to Expect From Achieve Life Sciences's Earnings
Achieve Life Sciences (NASDAQ:ACHV) is gearing up to announce its quarterly ear...
05-13 04:07
